Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502752 | 0.84 | NOS2 (0.58) | NOS2CYP3A4CYP3A5HTR1A | |
| SCHEMBL6576553 | 0.79 | NOS2 (0.53) | NOS2OPRM1OPRL1 | |
| SCHEMBL6576611 | 0.78 | NOS2 (0.55) | NOS2OPRM1OPRL1 | |
| Fumaric Acid SCHEMBL6579320 | 0.78 | NOS2 (0.61) | NOS2OPRM1OPRL1MEN1KMT2A | |
| Fumaric Acid SCHEMBL6579315 | 0.78 | NOS2 (0.61) | NOS2OPRM1OPRL1MEN1KMT2A | |
| Fumaric Acid SCHEMBL6577450 | 0.77 | NOS2 (0.60) | NOS2OPRM1OPRL1MEN1KMT2A | |
| Fumaric Acid SCHEMBL6577457 | 0.77 | NOS2 (0.60) | NOS2OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL6577453 | 0.76 | NOS2 (0.52) | NOS2OPRM1OPRL1CYP3A4MEN1 | |
| SCHEMBL31420190 | 0.74 | SLC6A4 (0.62) | OPRM1CYP3A4HTR1AMEN1KMT2A | |
| SCHEMBL15567036 | 0.73 | KMT2A (0.50) | CNR1ACKR3CYP3A4CYP3A5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743939-B2 | NITRIC OXIDE SYNTHASE INHIBITORS; SUCH AS 4-CHLORO-2-(((1)-4-(METHYLAMINO)-1-PHENYLBUTYL)OXY)BENZONITRILE | ASTRAZENECA AB (SE) | 2004-06-01 | — | — | US | disclosed |
| EP-1263714-B1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030105161-A1 | Novel phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105161-A1 | Novel phenylheteroalkylamine derivatives | NOS1, CYP1A1, NOS2 | NOS2 3/4885CNR1 144/4885OPRM1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.